Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | ANPEP | P15144 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27311776 | 0.90 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ATSHRHDAC8 | |
| SCHEMBL23462265 | 0.88 | ATM (0.48) | ALDH1A1MEN1KMT2ATSHRHDAC8 | |
| SCHEMBL8249263 | 0.87 | MEN1 (0.42) | ALDH1A1MEN1KMT2ATSHRHDAC8 | |
| SCHEMBL16064698 | 0.86 | MEN1 (0.44) | ALDH1A1MEN1KMT2ATSHRHDAC8 | |
| SCHEMBL30759145 | 0.83 | MEN1 (0.42) | ALDH1A1MEN1KMT2ATSHRHDAC8 | |
| SCHEMBL18103727 | 0.82 | CTSS (0.49) | ALDH1A1MEN1KMT2ATSHRHDAC8 | |
| SCHEMBL18103662 | 0.82 | CTSS (0.49) | ALDH1A1MEN1KMT2ATSHRHDAC8 | |
| SCHEMBL19192765 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AMMP2ANPEP | |
| SCHEMBL85695 | 0.79 | CYP3A4 (0.53) | ALDH1A1MEN1KMT2AMMP2ANPEP | |
| SCHEMBL84794 | 0.79 | CYP3A4 (0.53) | ALDH1A1MEN1KMT2AMMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-25 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| EP-4069223-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | Anakuria Therapeutics, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20210186935-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | US | disclosed |
| WO-2021113665-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | ALDH1A1 2625/4885MEN1 3780/4885KMT2A 2029/4885 |
| US-20210186935-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | ALDH1A1 4627/4885MEN1 241/4885KMT2A 3977/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | ALDH1A1 2625/4885MEN1 3780/4885KMT2A 2029/4885 |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | ALDH1A1 4627/4885MEN1 241/4885KMT2A 3977/4885 |
| US-11819476-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | ALDH1A1 4445/4885MEN1 286/4885KMT2A 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.